OTCMKTS:BIXT Bioxytran (BIXT) Stock Price, News & Analysis $0.12 0.00 (0.00%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsSEC FilingsShort Interest About Bioxytran Stock (OTCMKTS:BIXT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bioxytran alerts:Sign Up Key Stats Today's Range$0.11▼$0.1250-Day Range$0.08▼$0.1252-Week Range$0.07▼$0.19Volume12,897 shsAverage Volume84,183 shsMarket Capitalization$20.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.Read More… 24/7 Automated Profits in Crypto (Ad)The 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.Register for the FREE Workshop Now & get $10 in Bitcoin Bioxytran Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks5th Percentile Overall ScoreBIXT MarketRank™: Bioxytran scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bioxytran.Read more about Bioxytran's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioxytran is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioxytran is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the outstanding shares of Bioxytran have been sold short.Short Interest Ratio / Days to CoverBioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioxytran does not currently pay a dividend.Dividend GrowthBioxytran does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the outstanding shares of Bioxytran have been sold short.Short Interest Ratio / Days to CoverBioxytran has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for BIXT on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bioxytran insiders have not sold or bought any company stock.Percentage Held by Insiders70.00% of the stock of Bioxytran is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Bioxytran's insider trading history. Receive BIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. Email Address BIXT Stock News HeadlinesDIAM:CA Star Diamond CorporationSeptember 21, 2024 | seekingalpha.comBioxytran, Inc. (BIXT)August 29, 2024 | finance.yahoo.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 24, 2024 | Timothy Sykes (Ad)Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen CarrierJuly 18, 2024 | globenewswire.comBioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's PatientsJune 27, 2024 | globenewswire.comBIXT: Carbohydrate Drug Design in the Fight Against VirusesMarch 20, 2024 | msn.comBioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 AntagonistMarch 6, 2024 | globenewswire.comBioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19February 21, 2024 | finance.yahoo.comSee More Headlines BIXT Stock Analysis - Frequently Asked Questions How have BIXT shares performed this year? Bioxytran's stock was trading at $0.15 at the start of the year. Since then, BIXT stock has decreased by 23.3% and is now trading at $0.1150. View the best growth stocks for 2024 here. How do I buy shares of Bioxytran? Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bioxytran own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), bluebird bio (BLUE), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX). Company Calendar Today10/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:BIXT CUSIPN/A CIK1445815 Webwww.bioxytraninc.com Phone(617) 454-1199FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,280,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-2,417.46% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-5.75Miscellaneous Outstanding Shares177,204,000Free Float53,387,000Market Cap$20.38 million OptionableNot Optionable Beta-0.89 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (OTCMKTS:BIXT) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.